menu
    • menu

    Company profile for Harpoon Therapeutics

    NEW Drugs in Dev: 7
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases. At the heart of Harpoon’s approach is a novel antibody-derived platform called TriTAC™ (Tri-specific T cell Activating Construct) designed for targeted penetration and destruction of solid tumor malignancies, and engineered to bind to human serum ...
    Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases. At the heart of Harpoon’s approach is a novel antibody-derived platform called TriTAC™ (Tri-specific T cell Activating Construct) designed for targeted penetration and destruction of solid tumor malignancies, and engineered to bind to human serum albumin for improved therapeutic schedule and patient convenience.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Harpoon TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4000 Shoreline Court, Suite 250 South San Francisco, CA 94080 650-443-7400
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.harpoontx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck Advances Lung Cancer Strategy With Daiichi Deal And Combo Plans
    Merck Advances Lung Cancer Strategy With Daiichi Deal And Combo Plans

    06 Aug 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/merck-advances-lung-cancer-attack-pocketing-170m-daiichi-and-plotting-adc-trispecific-combo

    FIERCE BIOTECH
    06 Aug 2024
    Share Share
    Merck completes acquisition of Harpoon Therapeutics
    Merck completes acquisition of Harpoon Therapeutics

    12 Mar 2024

    // INDIAN PHARMA POST

    https://www.indianpharmapost.com/news/merck-completes-acquisition-of-harpoon-therapeutics-15379

    INDIAN PHARMA POST
    12 Mar 2024
    Share Share
    Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
    Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

    08 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240108498651/en

    BUSINESSWIRE
    08 Jan 2024
    Share Share
    Harpoon Therapeutics Strengthens Leadership Team
    Harpoon Therapeutics Strengthens Leadership Team

    26 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/12/26/2801063/0/en/Harpoon-Therapeutics-Strengthens-Leadership-Team.html

    GLOBENEWSWIRE
    26 Dec 2023
    Share Share
    Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation
    Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation

    19 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/19/2798452/0/en/Harpoon-Therapeutics-Abstract-for-HPN328-Accepted-for-Rapid-Oral-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-Genitourinary-Cancers-Symposium.html

    GLOBENEWSWIRE
    19 Dec 2023
    Share Share
    Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in RRMM at ASH 2023
    Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in RRMM at ASH 2023

    11 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/12/2794338/0/en/Harpoon-Therapeutics-Presents-HPN217-Phase-1-Clinical-Data-in-Relapsed-Refractory-Multiple-Myeloma-RRMM-at-ASH-2023-and-Announces-Selection-of-Recommended-Phase-2-Dose-RP2D.html

    GLOBENEWSWIRE
    11 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search